SK Biopharmaceuticals will divest a 12% stake in Arvelle, which is looking to commercialise an epilepsy drug treatment, through the acquisition.

Angelini Pharma, a subsidiary of conglomerate Angelini, agreed yesterday to buy Arvelle Therapeutics, a central nervous system (CNS) disorder drug developer spun off by pharmaceutical company Axovant, for up to $960m. The deal will involve a $610m upfront payment, with up to $350m in additional capital to be paid should Arvelle‚Äôs epilepsy drug, cenobamate, achieve…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.